hyperlipoproteinaemia type 1
Metabolic · 2015–2022
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| triglycerides, medium chain Dietary management of conditions requiring a source of medium chain triglycerides (including chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long… | Mar 2022 | Recommended | none received |
| triglycerides, long chain; triglycerides, medium chain Dietary management in patients with intractable seizures requiring ketogenic diet, glucose transport protein defect, or pyruvate dehydrogenase deficiency… | Mar 2017 | Recommended | no section in document |
| triglycerides medium chain formula Upgrade in the nutritional formula for patients with hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, chylous ascites, and chylothorax. | Nov 2015 | Recommended | none received |
What the PBS pays
$2M in government benefit over 2024–25, across 5,167 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| triglycerides medium chain formula | $1.9M |
| triglycerides, long chain; triglycerides, medium chain | $0.1M |
| triglycerides, medium chain | $0.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.